title: Methodology of clinical trials in lung cancer.
abstract: The identification of new targets in cancer biology has changed the traditional approach to cancer diagnosis and treatment and therefore also to drug development. The classical 'one size fits all' approach needed to be modified into a tailored approach that took into account the patient-to-patient variation. Innovative trials are warranted, based on the integration of new types of design and integrating the knowledge coming from new disciplines like bioinformatics, biostatistics, epidemiology and health economics. Several initiatives have started at national levels but also in large pan-European academic organizations [like the European Organization for Research and Treatment of Cancer (EORTC)] in the scope of generating a harmonized healthcare landscape across Europe.
authors.affiliation: EORTC Headquarters, Brussels, Belgium.
authors.forename: Jessica
authors.initials: J
authors.lastname: Menis
authors.affiliation: Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. benjamin.besse@gustaveroussy.fr.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Besse
authors.affiliation: EORTC Headquarters, Brussels, Belgium.
authors.forename: Denis
authors.initials: D
authors.lastname: Lacombe
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D002986:Clinical Trials as Topic / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D025202:Molecular Diagnostic Techniques; D058990:Molecular Targeted Therapy; D018579:Patient Selection; D057285:Precision Medicine; D011237:Predictive Value of Tests; D012107:Research Design
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
keywords: Clinical trial; design; lung cancer